1 |
Shimizu A, Shirai I, Ogawa K, Miura A, Haruhara K, Oshiro K, Hamaguchi A, Yokote S, Okabe M, Ueda H, Tsuboi N, Ikeda M, Yokoo T. Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies. Intern Med 2022;61:3703-8. [PMID: 36171121 DOI: 10.2169/internalmedicine.0241-22] [Reference Citation Analysis]
|
2 |
Dioverti V, Salto-alejandre S, Haidar G. Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”. Curr Transpl Rep 2022. [DOI: 10.1007/s40472-022-00385-y] [Reference Citation Analysis]
|
3 |
Maekura C, Muramatsu A, Nagata H, Okamoto H, Onishi A, Kato D, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Okumura K, Inaba T, Nukui Y, Kuroda J. Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature. Infect Drug Resist 2022;15:2723-8. [PMID: 35668857 DOI: 10.2147/IDR.S360238] [Reference Citation Analysis]
|
4 |
. Multiple drugs. Reactions Weekly 2022;1903:275-275. [DOI: 10.1007/s40278-022-13837-y] [Reference Citation Analysis]
|